SEC Form 4 · accession 0000903423-18-000400
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
GLAXOSMITHKLINE PLC
10% Owner
Period of report
Jul 17, 2018
Accepted (ET)
Jul 17, 2018 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 17, 2018 | P | 80,000 | $12.50 | A | 1,934,006 | I | By S.R. One, Limited |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1S.R. One, Limited acquired 80,000 common shares of the Issuer in connection with the Issuer's offering. Shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (Reporting Person).